The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.
 
Chung-Han Lee
Honoraria - American Institute of Continuing Medical Education; Ideology Health; Intellisphere; Medscape; Research to Practice
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Cardinal Health; Eisai; Eisai; Exelixis; Merck; Pfizer/EMD Serono
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); Merck (Inst)
 
Howard Gurney
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Merck Serono
Travel, Accommodations, Expenses - AstraZeneca
 
Vagif Atduev
No Relationships to Disclose
 
Cristina Suárez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Miguel A Climent Duran
Honoraria - Bayer; Bristol-Myers Squibb; EUNSA; Ipsen; Janssen; MSD; Pfizer; Pierre Fabre; Roche
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Janssen; MSD; Roche
 
David William Pook
Honoraria - Bayer; Merck/Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol Myers Squibb Foundation; Bristol-Myers Squibb; Bristol-Myers Squibb; Cipla; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme (Inst); Merck/Pfizer; Merck/Pfizer; Pfizer; Pfizer (Inst)
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); SymVivo (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Astellas Pharma; Bristol-Myers Squibb; Janssen; Merck/Pfizer; Merck/Pfizer; Pfizer
 
Piotr Tomczak
No Relationships to Disclose
 
Philippe Barthelemy
Honoraria - Astellas Pharma; Bayer; BMS; Gilead Sciences; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer; SEAGEN
Consulting or Advisory Role - AAA/Endocyte/Novartis; Amgen; AstraZeneca; Bayer; BMS; Eisai; Gilead Sciences; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - BMS; IPSEN; Janssen-Cilag; Merck/Pfizer; MSD; Pfizer
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Amgen; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck; Oscotec; Sanofi
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); GI Innovation (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Taron Nalbandian
No Relationships to Disclose
 
Viktor Stus
No Relationships to Disclose
 
Thomas Ferguson
Research Funding - AstraZeneca (Inst); Janssen (Inst); MSD (Inst)
Travel, Accommodations, Expenses - BMS; MSD; Roche
 
Pawel Wiechno
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Merck; MSD; MSD; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Merck; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Pfizer
 
Erhan Gokmen
Stock and Other Ownership Interests - Immunogen; macrogenics
Honoraria - Abdi Ibrahim; Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb/Celgene; Genekor; Gilead Sciences; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Sandoz-Novartis
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; genekor; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pfizer; Roche
 
Louis Lacombe
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb/Celgene (Inst); IMV (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
 
Craig Gedye
Consulting or Advisory Role - BCAL Diagnostics; Bristol-Myers Squibb (Inst); CADEX Genomics; Merck Sharp & Dohme (Inst); Novotech
Speakers' Bureau - Limbic Oncology (Inst)
 
Joseph Burgents
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Manish Sharma
Employment - Merck
Stock and Other Ownership Interests - Merck; Regeneron
 
Xiang Peng
No Relationships to Disclose
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD